ArticleBMC pregnancy and childbirth2025
Evaluation of zonulin levels in pregnant women with hyperemesis gravidarum.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperemesis gravidarum (HG) represents a serious pregnancy complication which affects 0.5-2% of pregnancies through severe nausea and vomiting that causes dehydration and weight loss and disrupts electrolyte levels. The exact causes of HG remain unknown but research suggests that hormonal shifts and genetic susceptibility and gastrointestinal problems all play a role. The research investigated serum zonulin levels in pregnant women with HG to determine their relationship with disease severity.
methodsThis case-control study included 44 pregnant women with HG aged 18–35 years with a BMI < 25 and 44 healthy pregnant women with similar demographic characteristics. Pregnant women with HG were divided into three groups based on PUQE scores: mild (n = 16), moderate (n = 19), and severe (n = 9). Serum zonulin levels were measured in all participants using the ELISA method, and their relationship with clinical parameters was investigated.
resultsZonulin levels were significantly lower in the HG group (33.7 ± 11.2 ng/ml) compared to the control group (46.8 ± 6.5 ng/ml) (p < 0.001). Zonulin levels decreased progressively with increasing severity of HG; they were 41.8 ± 5.0 ng/ml in the mild group, 35.2 ± 7.8 ng/ml in the moderate group, and 24.9 ± 9.2 ng/ml in the severe group (p = 0.002). A strong negative correlation was found between zonulin levels and HG severity (r=-0.72, p < 0.001), daily vomiting frequency (r=-0.65, p < 0.001), keton positivity (r=-0.58, p < 0.001), and electrolyte imbalance (r=-0.47, p = 0.002). ROC analysis showed a cut-off point of 40.2 ng/ml with 77.3% sensitivity and 84.1% specificity (AUC = 0.83).
conclusionThe low serum zonulin levels in pregnant women with HG and their negative correlation with disease severity suggest that alterations in intestinal barrier function may play an important role in the pathogenesis of HG. Zonulin may be used as a potential biomarker for the diagnosis and severity assessment of HG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.